Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs

Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous...

Full description

Bibliographic Details
Main Authors: Brenda Leeneman, Carin A. Uyl-de Groot, Maureen J. B. Aarts, Alexander C. J. van Akkooi, Franchette W. P. J. van den Berkmortel, Alfons J. M. van den Eertwegh, Jan Willem B. de Groot, Karin H. Herbschleb, Jacobus J. M. van der Hoeven, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Albert J. ten Tije, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, John B. A. G. Haanen, Margreet G. Franken
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
metastatic melanoma
healthcare costs
real-world data
immunotherapy
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/12/4/1003

Internet

https://www.mdpi.com/2072-6694/12/4/1003

Similar Items